Histopathological diagnosis of graft rejection faces serious limitations in terms of accuracy and risk prediction.
High-throughput gene expression profiling can provide evidence of graft rejection before a clinical phenotype becomes apparent.
Combining decisions from a diverse set of algorithms can result in more stable predictions.
Microarray data are susceptible to the curse of dimensionality.
Determining the best set of hyperparameters for an ensemble can be challenging